PULSE BIOSCIENCES, INC.

Overview

Pulse Biosciences, Inc. is a medical-device company developing bioelectric medicine based on Nano-pulse Stimulation (NPS), also known as nanosecond pulsed-field ablation. Its technology uses short electrical pulses to target cells without relying on thermal treatment. The company’s nPulse System is its delivery platform; its development focus has shifted from dermatology toward cardiology and soft-tissue ablation, particularly systems for treating atrial fibrillation.[1]+2

The company describes its mission as developing and commercializing nano-pulse technology to improve and extend patients’ lives. Its principal executive office is in Miami, Florida; filings also describe prior European regulatory clearances for a dermatology system and an early AF study in Prague, rather than a broad current commercial presence. Product revenue was $350,000 in 2025 and $835,000 in the six months ended June 30, 2026, consistent with a business still centered on development and limited commercialization.[4]+5 [1]+10

Products & services

Pulse Biosciences’ nPulse platform combines a software-enabled console with disposable electrodes or applicators. It delivers tunable nanosecond electrical pulses to ablate targeted cells nonthermally. The platform was formerly called CellFX; the company discontinued its dermatology marketing in 2022 and now focuses its applications on cardiac procedures and the Vybrance system.[10]+2

The nPulse Vybrance Percutaneous Electrode System is a disposable needle electrode used with the nPulse console for percutaneous or intraoperative soft-tissue ablation. It is FDA 510(k)-cleared for those procedures, with a second needle size cleared in 2024. For symptomatic benign thyroid nodules, the system is intended to reduce nodule volume while preserving surrounding anatomy and thyroid function.[13]+2

The company is also developing investigational cardiac products: an endocardial catheter-and-console system for atrial-fibrillation ablation, and a surgical clamp intended for use during concomitant cardiac surgery. Both are being studied in pivotal U.S. IDE trials and are not described as cleared commercial cardiac products.[16]+3

For the first half of 2026, the company reported $835,000 in product revenue, all from limited-market-release Vybrance sales; no separate services revenue was reported.[20][9] [10]+11

Geographic presence

Pulse Biosciences’ latest reported principal executive office is at 3957 Point Eden Way, Hayward, California. Its FY2025 filing identified Hayward as the site of principal operations, including office and laboratory facilities, and described a Miami, Florida, office as its corporate headquarters at that time.[21][22]

The company has historically marketed its nPulse system in the United States, Canada, and certain limited European markets, and established an operating company in the Netherlands in 2022 to support European operations. By the end of 2025, it reported having no international sales force and very few U.S. employees with sales-and-marketing experience; the historical markets should not be taken as evidence of current sales activity.[23]

The available company information does not provide revenue by country or region, geographic revenue percentages, or employee counts by location.[24] [21]+3

Business segments

Pulse Biosciences reports one operating and reportable segment: research and development of its Nano-pulse Stimulation (NPS) technology. The company is managed as a single segment, with performance assessed and resources allocated on an entity-wide basis; accordingly, this is 100% of its reported segment structure, not a revenue contribution percentage.[25]

The segment’s focus includes developing the nPulse platform for atrial fibrillation, as well as surgical AF and selected other potential applications, including surgical soft-tissue ablation.[10] [25][10]

Company history

Pulse Biosciences’ technology research dates to around 2000. The company was incorporated in Nevada as Electroblate, Inc. on May 19, 2014, and in November 2014 combined technology from ThelioPulse, BioElectroMed and NanoBlate. Company-sourced biographies identify Richard Nuccitelli and Robert Levande as founders.[26]+2 The company adopted the Pulse Biosciences name in December 2015 and completed an initial public offering in May 2016.[29][30]

In 2021, the company received European CE Mark approval and U.S. FDA clearance for its CellFX dermatology system, followed by Health Canada approval and a limited commercial rollout. In 2022, Kevin Danahy became President and CEO, succeeding Darrin Uecker, while Robert W. Duggan became Executive Chairman; the company also announced a strategic change in focus.[31]+2

In 2023, Pulse initiated a first-in-human study of its nPulse cardiac catheter in patients with atrial fibrillation. FDA clearance of the CellFX nsPFA Percutaneous Electrode System followed in March 2024, and Paul LaViolette became President and CEO that May. In 2025, the company received FDA approval to begin the NANOCLAMP AF pivotal study of its surgical cardiac system. In 2026, it began enrolling patients in the NANOPULSE-AF pivotal catheter trial and reported completing enrollment in a study of its Vybrance electrode for benign thyroid nodules.[6]+5 [31]+13

Sources

• PULSE BIOSCIENCES, INC. — Full financial report (2025 Y)
  9 citations

  [1][2][6][7][8][22][23][24][36]
• PULSE BIOSCIENCES, INC. — Full financial report (2026 Q 2)
  14 citations

  [3][9][10][11][12][13][14][16][17][18][19][20][21][25]
• www.pulsebiosciences.com[4]
• www.sec.gov[5]
• PULSE BIOSCIENCES, INC. — Transcript (2026 Q 2)[15]
• people.equilar.com[26]
• people.equilar.com[27]
• www.sec.gov[28]
• www.sec.gov[29]
• investors.pulsebiosciences.com[30]
• PULSE BIOSCIENCES, INC. — Full financial report (2022 Q 2)[31]
• PULSE BIOSCIENCES, INC. — Transcript (2021 Y)[32]
• www.sec.gov[33]
• investors.pulsebiosciences.com[34]
• investors.pulsebiosciences.com[35]
• investors.pulsebiosciences.com[37]
• www.sec.gov[38]